MIRA's Ketamir-2 shows promise in treating diabetic neuropathy, with a Phase 2a trial expected by late 2025 and human data in ...

近日，启迪药业 集团 旗下拳头产品古汉养生精 相关研究成果《 Guhan Yangsheng Jing mitigates oxidative stress and ferroptosis to improve reproductive damage ...

Type 2 diabetes (T2D) may impair reward processing in the brain, as shown in a rat maze experiment. Rats with T2D exhibited weaker reward signals in the anterior cingulate cortex (ACC) and spent ...

Ketamir-2 Demonstrates Strong Efficacy in Diabetic Neuropathy Model, with Some Subjects Achieving Complete Symptom Reversal MIAMI, FLORIDA / ACCESS Newswire / April 16, 2025 / MIRA Pharmaceuticals, ...

Scientists have described onion as the cheapest and most easily available treatment for diabetes. Researchers said that they did this study on rats and got amazing results in it. The results of ...

More than 36 million Americans have type 2 diabetes, meaning their blood sugar levels are always top of mind. After all, when people with diabetes have blood sugar levels that are too low or too high, ...

MIRA Pharmaceuticals (MIRA) announced data demonstrating the efficacy of the oral ketamine analog, Ketamir-2, in a validated animal model of ...

In the study, Type 2 diabetes was induced in rats using a high-fat diet combined with a low dose of Streptozotocin (STZ). This resulted in hyperglycemia and neuropathic symptoms, including ...

MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic ...